 IRVINE, Calif., Oct. 07, 2021 GLOBE NEWSWIRE -- Eledon Pharmaceuticals, Inc. Eledon NASDAQ: ELDN, a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis ALS, announced their participation in the Northeast Amyotrophic Lateral Sclerosis Consortium NEALS which is being held virtually on October 7, 2021. Dr. Steve Perrin, Eledons President and Chief Scientific Officer, will participate in an industry panel roundtable discussing ALS clinical trial design, biomarkers and endpoints. In addition, a poster will be presented on the AT-1501 Phase 2 study in adults with ALS. 